PAP
ARQT icon

Persistent Asset Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Persistent Asset Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,810
Closed -$302K – 176
2024
Q4 		$302K Buy
+22,810
New +$250K 0.25% 82

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Persistent Asset Partners's ARQT Position: Q1 2025 in Review

Persistent Asset Partners sold out of Arcutis Biotherapeutics (ARQT) in Q1 2025, closing a stake of 22,810 shares — an estimated $302K sold.

Persistent Asset Partners first reported a position in ARQT in Q4 2024 and held it in 1 quarter. The position peaked at $302K in Q4 2024. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • Persistent Asset Partners reported no remaining Arcutis Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 22,810 Arcutis Biotherapeutics shares in Q1 2025, an estimated $302K.
  • Persistent Asset Partners first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Persistent Asset Partners's Arcutis Biotherapeutics position peaked at $302K in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on Persistent Asset Partners's 13F filing for Q1 2025, filed 13 May 2025.